Healthcare ❯ Pharmaceuticals

Vaccines

COVID-19 Vaccines COVID-19 Vaccine RSV Vaccine Covid-19 HPV Vaccine HPV Vaccines COVID-19 Covid-19 Vaccine Mpox Vaccine AstraZeneca Covid Vaccine Covid Vaccine Flu Vaccination Influenza Vaccine CSL's Seqirus Injectable Treatments Adult Immunizations Regulatory Affairs Immunization Products Combination Vaccines Manufacturing Safety Vaccine Efficacy Safety Data Specific Vaccines Sales Decline Covid-19 Vaccines Gardasil

Moderna Reaches Up to $2.25 Billion LNP Patent Settlement, Pays $950 Million Upfront

The settlement grants Moderna a global license with no royalties, leaving a narrow government‑liability appeal as the only remaining issue.

Stories older than 24h

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Pfizer Sets 2026 Targets Below Wall Street as COVID Sales Fade, Patent Pressure Builds

Pfizer Lifts 2025 EPS Outlook, Targets $7.7 Billion in Savings as Dividend Draws Interest

Pfizer’s Updated COVID-19 Vaccine Shows Strong Phase 3 Immune Response for 2025–2026 Formula

Merck Launches $3 Billion Cost-Optimization Program Following Q2 Revenue Miss

House Judiciary Committee Subpoenas Pfizer Scientist Over 2020 Vaccine Timing Allegations